Radiofrequency Ablation Combined with Carrizumab Compared to Carrizumab Alone for Treating Moderate to Advanced Liver Cancer

What this Trial Is About

Researchers are studying whether patients with advanced hepatocellular carcinoma HCC, a type of liver cancer, can benefit more from a combination of radiofrequency ablation RFA and the PD-1 immunosuppressant drug carrizumab compared to carrizumab alone. This study is a phase 2 trial that involves 120 patients divided into two groups to assess progression-free survival PFS and other outcomes. The research aims to understand which treatment approach may better control tumor growth in this patient population. The study compares two treatment methods one group receives RFA combined with carrizumab, where RFA uses heat to destroy cancer cells, and the other group receives carrizumab alone. Patients in each group are monitored over an average of four years. The study is double-blinded and non-randomized, meaning neither patients nor doctors know who is receiving which treatment during the trial. Participants will undergo regular assessments including imaging scans like CT or MRI to measure tumor response, clinical evaluations, and laboratory tests. Researchers will track progression-free survival as the main outcome and also measure response rates, disease control, overall survival, and duration of response throughout the study. Safety and organ function are monitored, and the total participation time averages about four years from the start of treatment to study completion.

RFA Plus Carrizumab vs Carrizumab Alone for HCC